Vaccines for Tomorrow

The scope of Sanofi Pasteur’s Research & Development activities is vast and complex, encompassing the entire chain of events before a new vaccine becomes available – from understanding a disease and its biological foundations, to clinical development and testing, to obtaining health authorities’ approval for marketing the new vaccine.

We have currently vaccines in development or submitted for approval to meet the specific needs of different segments of the population (influenza, vaccines combination, etc.) or unmet medical needs (respiratory syncytial virus, etc.).

PHASE I PHASE II PHASE III REGISTRATION
Herpes Simplex Virus Type 2
HSV-2 therapeutic vaccine (1)
 
Fluzone HD
Pediatric
 
VerorabVax® (VRVg)
Purified vero rabies vaccine
 
SHAN 6
Pediatric hexavalent vaccine
Yellow Fever
Vaccine produced in vero cells
 
Next Gen PCV (2)
Pneumococcal Conjugate Vaccine
 
MenQuadfiTM
Meningococcal ACYW conjugate vaccine, US/EU 6w+
   
   
Respiratory syncytial virus
Infants 4-month and older vaccines (Ph 1/2)
Get more information
 
nirsevimab (5)
Respiratory syncytial virus
Monoclonal antibodyGet more information
   
   
COVID-19
Recombinant-protein (3)
       
   
COVID-19
mRNA (Ph 1/2) (4)
       
   
Meningitis B
(Ph 1/2)
       
  New molecular entities   Additional indications   Publication date: May 2021

(1) Developed in collaboration with Immune Design/Merck
(2) Developed in collaboration with SK
(3) Developed in collaboration with BARDA and GSK
(4) Developed in collaboration with Translate Bio
(5) Developed in collaboration with AstraZeneca

Related article

Inoculation Innovation: Bringing New Technology to Vaccines